炎症性肠病中的粘液相关细菌和代谢物:从内部到洞察力
Xinyu Wang1, LinLin He1, Yue Dong1
1Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, China.
NPJ biofilms and microbiomes
|January 30, 2026
概括
炎症性肠道疾病 (IBD) 涉及慢性肠道炎症. 与粘膜相关的细菌及其代谢物,不同于便细菌,是IBD病变发生的关键因素和潜在的诊断标志物.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 是一种具有复杂原因的慢性胃肠道疾病.
- 肠道微生物群和代谢物越来越被认为是IBD的关键病原性因素.
- 最近的研究强调了粘膜相关细菌的重要性,这些细菌与肠道上皮直接相互作用,而不是便细菌.
研究的目的:
- 审查目前关于粘膜相关细菌及其代谢物在IBD病变发生过程中的作用的证据.
- 探索粘膜相关细菌驱动的代谢变化的诊断潜力.
- 讨论针对IBD中的粘膜特异性微生物群-代谢物轴的新型治疗策略.
主要方法:
- 文献综述综合研究IBD,肠道微生物群和粘膜代谢物.
- 对比IBD患者便和粘膜相关细菌群体的研究分析.
- 检查关于细菌-上皮层相互作用和免疫调节的机制研究.
主要成果:
- IBD患者表现出粘膜相关细菌的失生症,随着 fakultative anaerobes 的增加和有益细菌的减少.
- 改变的粘膜代谢物,包括短链脂肪酸 (SCFA) 和三甲基胺-N-氧化物 (TMAO),与IBD有关.
- 粘菌相关细菌通过特定途径 (例如TLR4,粘素降解) 直接影响肠道屏障完整性和免疫反应.
结论:
- 与粘膜相关的细菌及其代谢物代表IBD与光线微生物群相比,具有独特的病原性因素.
- 粘膜细菌和代谢物的变化显示为IBD的早期诊断生物标志物具有前途.
- 向粘膜特定的细菌和代谢物为IBD管理提供了新的治疗途径,推进了精准医学.
更多相关视频
相关概念视频
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
986
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
986
01:21Inflammatory Bowel Disease V: Surgical Management
517
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
517
01:29Inflammatory Bowel Disease IV: Pharmacological Management
605
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
605
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
738
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
738
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
228
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
228